Attribution of expenses by nature to their function [axis] Breakdown of Revenue (2025)
Scenario Breakdown of Revenue (2025)
| S.No. |
Ticker |
Company |
Market Cap |
P/E |
P/S |
Total Debt (Qtr) |
| 1 |
LLY
|
ELI LILLY & Co |
795.68 Bn |
38.57 |
12.21 |
42.50 Bn |
| 2 |
JNJ
|
Johnson & Johnson |
583.58 Bn |
21.78 |
6.20 |
47.93 Bn |
| 3 |
ABBV
|
AbbVie Inc. |
376.99 Bn |
90.30 |
6.16 |
61.44 Bn |
| 4 |
MRK
|
Merck & Co., Inc. |
295.59 Bn |
16.18 |
4.55 |
49.34 Bn |
| 5 |
GSK
|
GSK plc |
292.35 Bn |
28.91 |
6.73 |
23.56 Bn |
| 6 |
AMGN
|
Amgen Inc |
187.85 Bn |
24.37 |
5.11 |
54.60 Bn |
| 7 |
GILD
|
Gilead Sciences, Inc. |
169.62 Bn |
19.91 |
5.76 |
24.94 Bn |
| 8 |
PFE
|
Pfizer Inc |
157.76 Bn |
20.41 |
3.27 |
64.80 Bn |